Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CloFluBu versus BuCyMel conditioning before allogeneic stem cell transplantation in pediatric AML
NL-OMON53923Phase 3Not yet recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jun 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clofarabine, fludarabine, busulfan, cyclophosphamide and melphalan in acute myeloid leukemia (AML) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: 2-year GVHD-free relapse-free survival. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
clofarabinefludarabinebusulfancyclophosphamidemelphalan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53923.